Premium
Radiopharmaceutical preparation of a monoclonal antibody, lym‐1, and its F(ab') 2 fragment for imaging lymphoma with In‐111
Author(s) -
Mills Stanley L.,
Denardo Sally J.,
DeNardo Gerald L.,
Deshpande Shrikant V.,
McCall Michael,
Meares Claude,
Epstein Alan L.
Publication year - 1989
Publication title -
journal of labelled compounds and radiopharmaceuticals
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.432
H-Index - 47
eISSN - 1099-1344
pISSN - 0362-4803
DOI - 10.1002/jlcr.2580270403
Subject(s) - chemistry , monoclonal antibody , molecule , lymphoma , fragment (logic) , antibody , radiochemistry , microbiology and biotechnology , pathology , immunology , organic chemistry , medicine , computer science , biology , programming language
(S)‐4‐[2,3 bis[bis(carboxymethylamino)]propyl]phenyl isothio‐cyanate (CITC) was used to attach In‐111 to an intact monoclonal antibody (Lym‐1) or its fragment F(ab') 2 to produce two new radiopharmaceuticals. Immunoreactivity of the Lym‐1, specific for B cell lymphoma, was not affected by the coupling reaction for 1.0 and 4.3 CITC molecules per whole antibody and 3.0 CITC molecules per F(ab') 2 fragment. Both retained in excess of 90% immunoreactivity even at the level of 25 mCi of In‐111 per mg of Lym‐1 and 15 mCi per mg F(Ab') 2 . The labeling reaction produced yields in excess of 98% eliminating the requirement for routine purification of the final radiopharmaceutical.